Loading
A phase 1/2 trial of Nivolumab, Docetaxel, PM8002 in cervical cancer and colorectal cancer, run by Bristol-Myers Squibb, now recruiting.
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04895709 by Bristol-Myers Squibb, with 1109 participants planned, started 2021-05-27 and due to reach its primary completion in 2031-08-31. Interventions recorded: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig. Conditions listed: Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PM8002, Docetaxel, Non-small-cell lung cancer.
Shares PM8002, Bristol Myers Squibb, Nivolumab.
Shares PM8002, Bristol Myers Squibb, Nivolumab.
Shares PM8002, Bristol Myers Squibb.
Shares PM8002, Bristol Myers Squibb.
Shares PM8002, Bristol Myers Squibb, Non-small-cell lung cancer.
Shares PM8002, Bristol Myers Squibb, Non-small-cell lung cancer.
Shares PM8002, Bristol Myers Squibb, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/